Thrombocytosis pathophysiology: Difference between revisions

Jump to navigation Jump to search
Faizan Sheraz (talk | contribs)
Jyostna Chouturi (talk | contribs)
No edit summary
 
(One intermediate revision by one other user not shown)
Line 3: Line 3:


{{Thrombocytosis}}
{{Thrombocytosis}}
{{CMG}}
{{CMG}} {{AE}}{{Faizan}}
==Overview==
==Overview==
== Pathophysiology==  
== Pathophysiology==  
Line 18: Line 18:
[[Category:Disease]]
[[Category:Disease]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Oncology]]
[[Category:Needs content]]
[[Category:Needs content]]

Latest revision as of 15:48, 30 August 2015

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Thrombocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombocytosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombocytosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombocytosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombocytosis pathophysiology

CDC on Thrombocytosis pathophysiology

Thrombocytosis pathophysiology in the news

Blogs on Thrombocytosis pathophysiology

Directions to Hospitals Treating Thrombocytosis

Risk calculators and risk factors for Thrombocytosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]

Overview

Pathophysiology

Thrombocytosis is either reactive or autonomous. In one study of 91 patients with platelet count >600,000, 70% were reactive and 22% autonomous. In 280 patients with platelet count >1,000,000 82% were reactive and 14% were autonomous. 8% had both. Among reactive causes of thrombocytosis, infection (30%), Post-surgical (15%), Both (30%), Malignancy (10%), Post splenectomy (10%) and acute blood loss/iron deficiency (10%) are the most common causes.

Autonomous causes of thrombocytosis include Essential Thrombocytosis, Chronic Myelogenous Leukemia (CML), Polycythemia Vera, Agnogenic Myeloid Metaplasia and Myelodysplasia. The degree of thrombocytosis does not help determine whether the thrombocytosis is reactive or not.

References

Template:WH Template:WS